A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a ...
Shares of weight-loss drug developer Metsera jumped nearly 42% in a strong Nasdaq debut on Friday, valuing the ARCH Venture ...
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...
Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...
The rise of GLP-1 agonist weight loss drugs has prompted the supplement industry to launch a bevy of “natural alternatives” to pharmaceutical compounds like Ozempic and Wegovy. But do they actually ...
One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...